Applications Of Mechanical Ventricular Assistance

Skinner, David B.; Anstadt, G L; Camp, Thomas F.

doi:10.1097/00000658-196709000-00016

Cited by 20 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 26 , 27 ]) [ 26 ]. The Anstadt Cup was able to support the circulation for 2–3 days in animals with ventricular fibrillation; however, long-term experimental results were never satisfactory [ 28 ]. In humans, the device was tested in only a few clinical trials, in which it was applied after prolonged periods of open cardiac massage ranging from 40 minutes to 12 hours [ 29 , 30 ].…”

Section: Cardiac Compression and Resuscitation: A Brief Historymentioning

confidence: 99%

The CorInnova Implantable Cardiac Assist System for Direct Cardiac Compression

Letsou¹,

Bolch²,

Hord³

et al. 2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

The CorInnova cardiac compression device (CorInnova, Inc., Houston, TX, USA) is designed to provide direct biventricular support, increase cardiac output, and improve ventricular unloading in patients with heart failure. Placed within the pericardium and surrounding both ventricles, the device has two concentric sets of thin-film polyurethane chambers: (1) inner (epicardial) saline-filled chambers that conform intimately to the epicardial surface, eradicating any gaps in the interface between the device and the heart; and (2) outer air-filled chambers cycled to provide epicardial compression during systole and negative epicardial pressure during diastole, consistent with physiological cardiac contraction and relaxation. A superelastic, collapsible Nitinol frame gives the device structure, enables minimally invasive self-deployment, and enhances diastolic filling. Preclinical testing has been extremely promising, with improvements in cardiac output and other cardiac parameters in animal heart failure models. This potentially transformative technology is moving rapidly toward first-in-human use. The CorInnova device may provide an effective device-based solution for patients with heart failure who currently have few or limited mechanical cardiac support options, including patients with biventricular cardiac failure, those with right heart failure, those who are older, and those who are of smaller size. It can be removed easily and requires minimal maintenance. An important, unique feature of this technology is that it provides mechanical cardiac assistance without blood contact or need for anticoagulation. The CorInnova device may be particularly important for those patients who have contraindications to anticoagulation due to allergy, neurological bleeds, or preexisting hemorrhage. No other mechanical circulatory support device addresses these underserved heart-failure populations.

show abstract

Section: Cardiac Compression and Resuscitation: A Brief Historymentioning

confidence: 99%

The CorInnova Implantable Cardiac Assist System for Direct Cardiac Compression

Letsou¹,

Bolch²,

Hord³

et al. 2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…The Anstadt device has been shown to provide adequate total circulatoiy support with minimal damage to the myocardium. In an article which reviews the physiological effects of the Anstadt device during ventricular fibrillation in dogs (Skinner et al, 1967), mean arterial pressures greater than 75 mmHg were consistently reported in animals which were supported for 24 hours or more. Cardiac outputs were reported to achieve an overall average which reached 49 percent of control levels and regional blood flow was found to be adequate to all vital organs.…”

Section: Previous Assist Devicesmentioning

confidence: 99%

“…Some problems were associated with use of the Anstadt cup. Two related adverse effects of the Anstadt device manifested as a banding effect of the ventricular sealing rim on the right ventricular outflow tract and histological lesions found in this same area of the heart after application of the device (Skinner et al, 1967). These lesions were attributed to the rigidity of the external housing.…”

Section: Previous Assist Devicesmentioning

confidence: 99%

Evaluation of a direct systolic cardiac augmentation device on a canine heart during global postischemic dysfunction

Kudej

View full text Add to dashboard Cite

TABLE OF CONTENTS ACKNOWLEDGEMENTS ix CHAPTER I. INTRODUCTION 1 CHAPTER 2. LITERATURE REVIEW 4 Myocardial stunning 4 Description 4 Mechanism of development S Generation of oxygen-derived free radicals 5 Calcium overload 10 Excitation-contraction uncoupling due to sarcoplasmic reticulum dysfunction Other possible mechanisms Previous assist devices CHAPTER 3. DESCRIPTION OF THE HEART CUFF CHAPTER 4. OBJECTIVES OF THE STUDY

show abstract